Relapsed/Refractory

The term “relapsed” refers to disease that reappears or grows again after a period of remission. The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.

Some drugs that are used for other lymphomas may at times be considered for use in patients with angioimmunoblastic T-cell lymphoma (AITL) that has relapsed or is refractory to other treatments, including:

• Alemtuzumab (Campath)
• Bendamustine (Treanda)
• Bortezomib (Velcade)
• Cyclosporine
• Fludarabine (Fludara)
• Gemcitabine (Gemzar)
• Pralatrexate (Folotyn)
• Rituximab (Rituxan)
• Romidepsin (Istodax)
• Belinostat (Beleodaq)

Learn More

To learn more about AITL, view the T-Cell Lymphomas Guide. Want to talk to someone? For answers to lymphoma-related questions 
and resources, contact our Lymphoma Resource Center at (800) 500-9976 or [email protected].